Invention Grant
US08742102B2 Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization
有权
通过优先结晶对外消旋二氢-1,3,5三嗪的对映异构体分离方法
- Patent Title: Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization
- Patent Title (中): 通过优先结晶对外消旋二氢-1,3,5三嗪的对映异构体分离方法
-
Application No.: US13138728Application Date: 2010-03-26
-
Publication No.: US08742102B2Publication Date: 2014-06-03
- Inventor: Matthias Helmreich , Claus-Peter Niesert , Daniel Cravo , Gérard Coquerel , Guillaume Levilain , Saoussen Wacharine-Antar , Pascal Cardinael
- Applicant: Matthias Helmreich , Claus-Peter Niesert , Daniel Cravo , Gérard Coquerel , Guillaume Levilain , Saoussen Wacharine-Antar , Pascal Cardinael
- Applicant Address: FR Lyon
- Assignee: Poxel
- Current Assignee: Poxel
- Current Assignee Address: FR Lyon
- Agency: Nixon & Vanderhye P.C.
- Priority: EP09004315 20090326
- International Application: PCT/EP2010/054037 WO 20100326
- International Announcement: WO2010/109015 WO 20100930
- Main IPC: C07D251/10
- IPC: C07D251/10 ; A61K31/53 ; A61P3/04
Abstract:
A new process for the enantiomeric separation of racemic 3,6-dihydro-1,3,5-triazine derivatives for the treatment of disorders associated with insulin-resistance syndrome, by preferential crystallization.
Public/Granted literature
- US20120071655A1 PROCESS FOR ENANTIOMERIC SEPARATION OF RACEMIC DIHYDRO-1,3,5, TRIAZINES VIA PREFERENTIAL CRYSTALLIZATION Public/Granted day:2012-03-22
Information query
